The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

Baodong Sun, Andrew V Schally, Gabor Halmos

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of various cancers. The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors. In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines. Of the 22 ovarian cancer specimens analyzed, 17 tumors (~77%) expressed mRNA for GRPR, 19 (~86%) showed NMBR mRNA and six (~27%) revealed BRS-3 mRNA. Thus, 14 of 22 specimens (~64%) expressed mRNAs for both GRPR and NMBR, and five (~23%) expressed all three subtypes. The expression of GRPR appeared to be greater in poorly differentiated ovarian carcinomas. A higher incidence of BRS-3 expression was observed in samples with tumor Stage IV (4/4, 100%) compared with Stage III (1/17, ~6%). mRNA for both GRPR and NMBR was also detected in OV-1063 and UCI-107 human ovarian cancer xenografts, but BRS-3 was found only in OV-1063, which originated from a metastatic tumor. In addition, functional receptors for bombesin/GRP were found in eight of 11 ovarian cancer specimens investigated and in both ovarian cancer lines by receptor binding assay. Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors. Some approaches based on bombesin/GRP receptor antagonists or targeted bombesin analogs could be considered for treatment of ovarian cancers. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalRegulatory Peptides
Volume90
Issue number1-3
DOIs
StatePublished - Jun 30 2000
Externally publishedYes

Fingerprint

Bombesin Receptors
Gastrin-Releasing Peptide
Messenger RNA
Ovarian Neoplasms
Bombesin
Tumors
Neoplasms
Ovarian epithelial cancer
Carcinoma
Polymerase chain reaction

Keywords

  • Bombesin receptor
  • BRS-3
  • Cancer therapy
  • GRPR
  • Hormone analogs
  • NMBR
  • Ovarian cancer metastasis
  • RT-PCR

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Neuroscience(all)

Cite this

The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. / Sun, Baodong; Schally, Andrew V; Halmos, Gabor.

In: Regulatory Peptides, Vol. 90, No. 1-3, 30.06.2000, p. 77-84.

Research output: Contribution to journalArticle

@article{509f3299b38742768edc5607ac9244d7,
title = "The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers",
abstract = "Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of various cancers. The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors. In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines. Of the 22 ovarian cancer specimens analyzed, 17 tumors (~77{\%}) expressed mRNA for GRPR, 19 (~86{\%}) showed NMBR mRNA and six (~27{\%}) revealed BRS-3 mRNA. Thus, 14 of 22 specimens (~64{\%}) expressed mRNAs for both GRPR and NMBR, and five (~23{\%}) expressed all three subtypes. The expression of GRPR appeared to be greater in poorly differentiated ovarian carcinomas. A higher incidence of BRS-3 expression was observed in samples with tumor Stage IV (4/4, 100{\%}) compared with Stage III (1/17, ~6{\%}). mRNA for both GRPR and NMBR was also detected in OV-1063 and UCI-107 human ovarian cancer xenografts, but BRS-3 was found only in OV-1063, which originated from a metastatic tumor. In addition, functional receptors for bombesin/GRP were found in eight of 11 ovarian cancer specimens investigated and in both ovarian cancer lines by receptor binding assay. Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors. Some approaches based on bombesin/GRP receptor antagonists or targeted bombesin analogs could be considered for treatment of ovarian cancers. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Bombesin receptor, BRS-3, Cancer therapy, GRPR, Hormone analogs, NMBR, Ovarian cancer metastasis, RT-PCR",
author = "Baodong Sun and Schally, {Andrew V} and Gabor Halmos",
year = "2000",
month = "6",
day = "30",
doi = "10.1016/S0167-0115(00)00114-2",
language = "English",
volume = "90",
pages = "77--84",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

AU - Sun, Baodong

AU - Schally, Andrew V

AU - Halmos, Gabor

PY - 2000/6/30

Y1 - 2000/6/30

N2 - Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of various cancers. The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors. In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines. Of the 22 ovarian cancer specimens analyzed, 17 tumors (~77%) expressed mRNA for GRPR, 19 (~86%) showed NMBR mRNA and six (~27%) revealed BRS-3 mRNA. Thus, 14 of 22 specimens (~64%) expressed mRNAs for both GRPR and NMBR, and five (~23%) expressed all three subtypes. The expression of GRPR appeared to be greater in poorly differentiated ovarian carcinomas. A higher incidence of BRS-3 expression was observed in samples with tumor Stage IV (4/4, 100%) compared with Stage III (1/17, ~6%). mRNA for both GRPR and NMBR was also detected in OV-1063 and UCI-107 human ovarian cancer xenografts, but BRS-3 was found only in OV-1063, which originated from a metastatic tumor. In addition, functional receptors for bombesin/GRP were found in eight of 11 ovarian cancer specimens investigated and in both ovarian cancer lines by receptor binding assay. Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors. Some approaches based on bombesin/GRP receptor antagonists or targeted bombesin analogs could be considered for treatment of ovarian cancers. Copyright (C) 2000 Elsevier Science B.V.

AB - Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of various cancers. The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors. In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines. Of the 22 ovarian cancer specimens analyzed, 17 tumors (~77%) expressed mRNA for GRPR, 19 (~86%) showed NMBR mRNA and six (~27%) revealed BRS-3 mRNA. Thus, 14 of 22 specimens (~64%) expressed mRNAs for both GRPR and NMBR, and five (~23%) expressed all three subtypes. The expression of GRPR appeared to be greater in poorly differentiated ovarian carcinomas. A higher incidence of BRS-3 expression was observed in samples with tumor Stage IV (4/4, 100%) compared with Stage III (1/17, ~6%). mRNA for both GRPR and NMBR was also detected in OV-1063 and UCI-107 human ovarian cancer xenografts, but BRS-3 was found only in OV-1063, which originated from a metastatic tumor. In addition, functional receptors for bombesin/GRP were found in eight of 11 ovarian cancer specimens investigated and in both ovarian cancer lines by receptor binding assay. Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors. Some approaches based on bombesin/GRP receptor antagonists or targeted bombesin analogs could be considered for treatment of ovarian cancers. Copyright (C) 2000 Elsevier Science B.V.

KW - Bombesin receptor

KW - BRS-3

KW - Cancer therapy

KW - GRPR

KW - Hormone analogs

KW - NMBR

KW - Ovarian cancer metastasis

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0034733778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034733778&partnerID=8YFLogxK

U2 - 10.1016/S0167-0115(00)00114-2

DO - 10.1016/S0167-0115(00)00114-2

M3 - Article

C2 - 10828496

AN - SCOPUS:0034733778

VL - 90

SP - 77

EP - 84

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3

ER -